BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 35218887)

  • 21. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
    Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
    Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.
    Marur S; Singh H; Mishra-Kalyani P; Larkins E; Keegan P; Sridhara R; Blumenthal GM; Pazdur R
    Semin Oncol; 2018 Aug; 45(4):220-225. PubMed ID: 30391014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
    Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
    Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90.
    Shah M; Mamtani R; Marmarelis ME; Hennessy S
    Clin Lung Cancer; 2023 May; 24(3):235-243. PubMed ID: 36935244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti-PD-(L)1 monotherapies in routine practice.
    Shah M; Hubbard RA; Mamtani R; Marmarelis ME; Hennessy S
    Pharmacoepidemiol Drug Saf; 2022 Oct; 31(10):1121-1126. PubMed ID: 35670103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
    Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T
    Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The real-world treatment characteristic and efficacy of immune checkpoint inhibitors in non-small cell lung cancer: Data from a retrospective cohort study.
    Zhang C; Shao J; Tang X; Wu J; Li P; Li W; Wang C
    Int Immunopharmacol; 2024 Jun; 134():112152. PubMed ID: 38761777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics.
    Liu W; Huo G; Chen P
    BMC Cancer; 2023 May; 23(1):458. PubMed ID: 37202730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy and influencing factors of immunotherapy combined with chemotherapy and bevacizumab in patients with non-small cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitors treatment failure].
    Wang C; Li Y; Guan Y; Yang SJ; Yin JC; Zhang CF; Guo QS; Shi WN
    Zhonghua Yi Xue Za Zhi; 2023 Apr; 103(16):1210-1216. PubMed ID: 37087404
    [No Abstract]   [Full Text] [Related]  

  • 31. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
    Cortellini A; Cannita K; Tiseo M; Cortinovis DL; Aerts JGJV; Baldessari C; Giusti R; Ferrara MG; D'Argento E; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Antonuzzo L; Mazzoni F; De Toma A; Signorelli D; Gelibter A; Targato G; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Filetti M; Bracarda S; Citarella F; Russano M; Cantini L; Nigro O; Buti S; Minuti G; Landi L; Ricciardi S; Migliorino MR; Natalizio S; Simona C; De Filippis M; Metro G; Adamo V; Russo A; Spinelli GP; Di Maio M; Banna GL; Friedlaender A; Addeo A; Pinato DJ; Ficorella C; Porzio G
    Eur J Cancer; 2021 May; 148():24-35. PubMed ID: 33721704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.
    Verschueren MV; Peters BJ; Bloem LT; Kruik VR; Uitvlugt EB; Bijsmans AR; Egberts AC; van de Garde EM
    Clin Lung Cancer; 2024 Mar; 25(2):119-127.e1. PubMed ID: 38246791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS
    Ricciuti B; Alessi JV; Elkrief A; Wang X; Cortellini A; Li YY; Vaz VR; Gupta H; Pecci F; Barrichello A; Lamberti G; Nguyen T; Lindsay J; Sharma B; Felt K; Rodig SJ; Nishino M; Sholl LM; Barbie DA; Negrao MV; Zhang J; Cherniack AD; Heymach JV; Meyerson M; Ambrogio C; Jänne PA; Arbour KC; Pinato DJ; Skoulidis F; Schoenfeld AJ; Awad MM; Luo J
    Ann Oncol; 2022 Oct; 33(10):1029-1040. PubMed ID: 35872166
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Papillon-Cavanagh S; Doshi P; Dobrin R; Szustakowski J; Walsh AM
    ESMO Open; 2020 Apr; 5(2):. PubMed ID: 32312757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50.
    Gainor JF; Rizvi H; Jimenez Aguilar E; Skoulidis F; Yeap BY; Naidoo J; Khosrowjerdi S; Mooradian M; Lydon C; Illei P; Zhang J; Peterson R; Ricciuti B; Nishino M; Zhang J; Roth JA; Grishman J; Anderson D; Little BP; Carter BW; Arbour K; Sauter JL; Mino-Kenudson M; Heymach JV; Digumarthy S; Shaw AT; Awad MM; Hellmann MD
    Ann Oncol; 2020 Mar; 31(3):404-411. PubMed ID: 32067682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices.
    Velcheti V; Chandwani S; Chen X; Pietanza MC; Piperdi B; Burke T
    Immunotherapy; 2019 Dec; 11(18):1541-1554. PubMed ID: 31774363
    [No Abstract]   [Full Text] [Related]  

  • 37. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
    Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
    ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
    Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
    Descourt R; Chouaid C; Pérol M; Besse B; Greillier L; Bylicki O; Ricordel C; Guisier F; Gervais R; Schott R; Auliac JB; Robinet G; Decroisette C
    Future Oncol; 2021 Aug; 17(23):3007-3016. PubMed ID: 34156285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Elkrief A; Riccuiti B; Alessi JV; Fei T; Kalvin HL; Egger JV; Rizvi H; Thummalapalli R; Lamberti G; Plodkowski A; Hellmann MD; Kris MG; Arcila ME; Baine MK; Rudin CM; Lito P; Ladanyi M; Schoenfeld AJ; Riely GJ; Awad MM; Arbour KC
    Oncologist; 2023 Nov; 28(11):978-985. PubMed ID: 37589215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.